Osool & Bakheet issues Q2 2024 earnings forecast
Argaam09/07/2024
GIB Capital previews Q2 2024 earnings
Argaam07/07/2024
Argaam09/07/2024
Argaam07/07/2024
| Last Trade | 128.80 |
| Change | (2.40) |
| Change (%) | (1.83) |
| Open | 131.40 |
| Low | 128.00 |
| High | 131.40 |
| Prev. Close | 131.20 |
| Change (3M) | (13.90 %) |
| Change (6M) | n/a |
| Volume | 100,189 |
| Turnover | 12,940,688.00 |
| Transactions | 1,607 |
| Market Value | 2,576.00 |
| Avg. Volume (3M) | 123,121.68 |
| Avg. Turnover (3M) | 16,775,425.78 |
| Avg. Transaction (3M) | 1,902.62 |
| Change(12M) | n/a |
| YTD | n/a |
|
Event Date
|
Event
|
Venue
|
|
|---|---|---|---|
|
30-06-2024
|
General Assembly | - | |
|
27-02-2024
|
listing date | - | |
|
14-02-2024
|
Surplus refund date | - | |
|
08-02-2024
|
Allocation Date | - | |
|
01-02-2024
|
IPO/ Subscription | - | |
| more | |||
Argaam Special27/02/2024
Argaam25/02/2024
| Report | Interim | Year |
| Avalon Pharma turns to profit of SAR 9.4M in Q1 2024 | 3 M | 2024 |
| Avalon Pharma’s profit rises 11% to SAR 65.8M in 2023 | 12 M | 2023 |
Argaam09/07/2024
Argaam07/07/2024
Argaam07/07/2024
| Date | Research firm | Rating |
|
|
Al Rajhi Capital | Overweight |
|
|
GIB Capital | Overweight |
|
|
SNB Capital | Overweight |
|
|
Forsa Financial | Initiation |
